Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: Darth Vader who wrote (65)	2/27/1998 9:17:00 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 359

Darth Vader; Are you guessing, or do you know that it was Sequana that dumped shares? How does the merger of SQNA with ARRS - now AXPH - affect the agreement with ABSC? It would seem to me that the purpose of the ABSC/Sequana agreement was to come up with great drug candidates and that is where AXPH comes in. It would be AXPH that would then get the candidates through the approval process. Walker CEO (?) of AXPH has an excellent reputation and in recent quarterly report of a few days ago said..."our drive to establish the company as the leading drug discovery company in the biotechnology industry." Not "one of" but -THE- leading drug discovery company. I like that attitude. If it was SQNA that sold shares then what does that mean?